Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | State-of-the-art first-line therapy for mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, explores the first-line treatment of patients with metastatic colorectal cancer (mCRC), including molecular drivers of disease such as microsatellite instability, as well as EGFR/BRAF/RAS mutations which can be targeted by immunotherapies or targeted therapies respectively. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3ZWhLDH